TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06380075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectralis FAF imaging
Description: Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optos imaging
Description: Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clarus imaging
Description: Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
Study: NCT05145868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Skills and Emotion Regulation Intervention
Description: The text-based intervention will provide alcohol reduction strategies and emotion regulation skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Text-messages will be sent that include no intervention content to serve as an attention control
Study: NCT06725290

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Surface Disease Index (OSDI) questionnaire
Description: The OSDI is a validated, self-administered questionnaire for assessing the presence and severity of ocular surface disease symptoms. The OSDI questionnaire includes 12 questions about the respondent's past week experience with the ocular symptoms, vision-related function, and environmental triggers

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Surface Disease Index (OSDI) questionnaire
Description: The OSDI is a validated, self-administered questionnaire for assessing the presence and severity of ocular surface disease symptoms. The OSDI questionnaire includes 12 questions about the respondent's past week experience with the ocular symptoms, vision-related function, and environmental triggers

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Surface Disease Index (OSDI) questionnaire
Description: The OSDI is a validated, self-administered questionnaire for assessing the presence and severity of ocular surface disease symptoms. The OSDI questionnaire includes 12 questions about the respondent's past week experience with the ocular symptoms, vision-related function, and environmental triggers
Study: NCT06726876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Manuka honey oral rinse.
Description: Name: Manuka Honey Oral Rinse~Description:~Dosage: Patients will use 20 ml of Manuka honey diluted in 100 ml of purified water.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the solution for a specified duration and avoid swallowing it.~Unique Elements:~Active Ingredient: Manuka honey, known for its unique antibacterial properties due to high levels of methylglyoxal (MGO).~Mechanism of Action: MGO and Non-Peroxide Activity (NPA) contribute to antibacterial potency, effective against antibiotic-resistant bacteria, and potential immunomodulatory effects that aid wound healing and tissue regeneration.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm.~Supplementary Care: Patients receive motivation and detailed oral hygiene instructions (proper tooth brushing technique, flossing, use of inte

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline rinses.
Description: Dosage: Patients will use 20 ml of normal saline.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the saline solution for a specified duration and avoid swallowing it.~Unique Elements:~Control Comparison: Provides a placebo comparison to evaluate the efficacy of the Manuka honey intervention.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm.
Study: NCT06010511

Intervention type: OTHER
Intervention: 3T MRI scan
Description: Conventional (3T) brain MRI scans will be used to determine global and functional markers of cerebral SVD, like WMH volume and presence of lacunes, microbleeds and superficial siderosis (3D T1, 3D FLAIR, SWI, DWI), hemodynamics (arterial spin labelling \& flow territory mapping) and white matter structural integrity (diffusion tensor imaging (DTI)). Furthermore, we want to measure structural integrity with a novel MR fingerprinting sequence and an inhomogeneous magnetization transfer (ihMT) MRI scan. We also want to apply a fMRI scan technique to measure CSF fluctuations in the 4th ventricle as a measure of brain glymphatics. Also the flow-territory mapping sequence is a non-standard sequence. Heart rate and respiratory signal will be measured during the scans (3T and 7T MRI) with standard vendor-supplied equipment.

Intervention type: OTHER
Intervention: 7T MRI scan
Description: Ultra-high field (7T) brain MRI scans will be used to determine WMH shape and other markers of cerebral SVD in or surrounding the WMH, like local enlarged perivascular spaces, (cortical) microinfarcts and microbleeds (T1, T2, FLAIR and T2\*) and vascular pulsatility (phase contrast MRI). Moreover, a recently implemented MRI technique to measure glymphatic flow in perivascular spaces will be used.

Intervention type: BEHAVIORAL
Intervention: Neuropsychological assessment
Description: * Mini-mental state examination~* Clock drawing~* 15-Word Verbal Learning Test, immediate and delayed~* Visual Association Test~* Stroop Color Word Test, 40 item version~* Trail Making Test A\&B~* Letter Digit Substitution Test~* Animal fluency test~* Hospital anxiety and depression scale~* Informant Questionnaire on Cognitive Decline in the Elderly

Intervention type: OTHER
Intervention: General baseline data
Description: Baseline data, such as age, sex, psychiatric comorbidity and medication lists will be extracted from the patient files.~Age (Year of birth); Years of education; BMI (height \& weight); Sex; Verhage scale (education); Smoking status; Blood values; Sleep habits; Waste-hip ratio; Blood pressure; Current/general cardiovascular health; Psychiatric comorbidity; medical history related to cardiovascular health.
Study: NCT05934903

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Cathodal direct current stimulation at 0 or 2mA will be applied to subjects

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Cathodal direct current stimulation at 0 or 2mA will be applied to subjects
Study: NCT06096415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-101 1mg
Description: ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABX-101 1mg
Description: ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
Study: NCT04856566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Marijuana, Hash, THC, or Grass
Description: Cannabis with low amount of THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Marijuana, Hash, THC, or Grass
Description: Cannabis with high amount of THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug with no THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug with no THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05 BAC Alcohol
Description: Amount of alcohol when consumed leads to BAC of 0.05

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05 BAC Alcohol
Description: Amount of alcohol when consumed leads to BAC of 0.05

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05 BAC Alcohol
Description: Amount of alcohol when consumed leads to BAC of 0.05

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.08 BAC Alcohol
Description: Amount of alcohol when consumed leads to BAC of 0.08
Study: NCT06345573

Intervention type: BEHAVIORAL
Intervention: Mental stress
Description: Two consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part).

Intervention type: BEHAVIORAL
Intervention: Mental stress
Description: Two consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part).
Study: NCT05795127

Intervention type: PROCEDURE
Intervention: First metatarsophalangeal joint arthrodesis
Description: Surgery leadin to bony uninon in firts metatarsophalangeal joint

Intervention type: PROCEDURE
Intervention: First metatarsophalangeal joint arthrodesis
Description: Surgery leadin to bony uninon in firts metatarsophalangeal joint
Study: NCT04856852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine-125+Chemotherapy
Description: Iodine-125: Iodine-125 if necessary, 0.6-0.8mCi, PD:120-150Gy Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
Study: NCT06096415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-101 2mg
Description: ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-101 2mg
Description: ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABX-101 2mg
Description: ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
Study: NCT06100913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)
Description: The study vaccine is an FDA-approved recombinant vesicular stomatitis virus (rVSV) expressing the envelope glycoprotein of Ebola virus Zaire (rVSV∆G-ZEBOV-GP). The dose of rVSV∆G-ZEBOV-GP vaccine has been chosen for this study as per package insert recommendations and based on clinical data. Participants receive 1.0 milliliter (mL) of the study vaccine administered intramuscularly in the deltoid muscle of the non-dominant arm.
Study: NCT04856852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection+Radiochemotherapy
Description: Surgical resection: Maximal surgical resection, including gross total resection, subtotal resection, and partial resection.~Radiation: total 60 Gy, 2 Gy per daily fraction (Monday to Friday) for 6 weeks. Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
Study: NCT05345301

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Event related desynchronization measurement
Description: Individuals will spend one hour and receive cues to open or close their hand while wearing a EEG cap and EMG sensors on their forearm.
Study: NCT04770948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 19 gauge needle
Description: EBUS-TBNA performed using 19G needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge needle
Description: EBUS-TBNA performed using 22G needle
Study: NCT04717817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) using an IMT Threshold device (Philips)
Description: Inspiratory muscle training on a daily basis prior to surgery during 2-3 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy
Description: Standard instructions and physiotherapy prior to surgery during 2-3 weeks
Study: NCT05757128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal Health Program
Description: The OHP intervention will comprise a psychosocial management program that will be adapted to the CHR population and will be accompanied by a structured workbook. Sessions are approximately 1 hour in duration and held weekly for 6 weeks, and every two weeks for the remaining 6 weeks. The OHP has three components: 1) assessment and engagement; 2) therapy sessions, and 3) maintenance integration.
Study: NCT06058325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy school lunch
Description: The healthy school lunch will be co-created together with school staff, parents, and children, and should be healthy according guidelines of the Dutch nutrition center.
Study: NCT03867643

Intervention type: BIOLOGICAL
Intervention: hepatitis B vaccine(HepB)
Description: Children with anti-HBs at a low level (\<10mIU/mL and \[10,100) mIU/mL) were received a dose of hepatitis B vaccine booster after informed consent.
Study: NCT06480318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: The device is portable and battery-powered to preserve the patient functional activity. The device has two channels and the parameters of each channel can be adjusted independently of the other. The device contains a power supply, amplifier and electrodes to give a warning. The power supply and amplifier are located within the TENS device. Electrodes are connected to the device via cables. The current produced in the power supply is increased in the amplifier and reaches the electrodes. The device is self-gel to facilitate the transmission of current between the electrodes made of carbon silicon alloy and the skin surface. In the research, a dual-channel, four-electrode (5 cm x 5cm) TENS device will be used. TENS application will be applied every 12 hours, twice and for 20 minutes, 24 hours after the surgery.
Study: NCT05538442

Intervention type: OTHER
Group type: OTHER
Intervention: Physiological recordings
Description: Physiological, cognitive, biological measurments
Study: NCT05115682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity Intermittent Exercise
Description: The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity Intermittent Exercise
Description: The participants will perform a low-volume, High-intensity Intermittent Exercise bout on a cycle ergometer. Peak exercise capacity of the study participants will be determined on a separate occasion using a ramp-up maximal oxygen consumption test (VO2peak). A single exercise bout will consist of a 7-minute warm-up on a cycle ergometer, followed by 6 1-minute intervals of cycling at individual maximal capacity and 75rpm (rotations per minute). These intervals will be interspersed with 1-min breaks of cycling at low resistance and 75rpm, and the session will conclude with a 3-minute cool-down interval (20 minutes in total).
Study: NCT05718024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-esketamine
Description: Dexmedetomidine-esketamine combination will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol-remifentanil
Description: Propofol and remifentanil will be infused during night-time (8 pm to 6:30 am) for ICU patients with mechanical ventilation.
Study: NCT04902547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education Workshop (PEWs)
Description: The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Tapering Program
Description: The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Tapering Program
Description: The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success.~Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up.
Study: NCT06331325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frenotomy
Description: Partial thickness procedure aiming to relocate high frenum attachment to a more apical level.
Study: NCT06332677

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: the main genes and expression by comparing the transcriptomic lipidomic profile
Description: To identify the main genes and pathways differentially expressed and the main factors associ- ated in order to evaluate the role of SUV420H1/H2
Study: NCT06331325

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frenectomy
Description: Full-thickness excision of the frenum down to the bone level and suturing by achieving primary closure.
Study: NCT06230042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Types of catheters
Description: One type of catheters were used for patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Types of catheters
Description: One type of catheters were used for patients
Study: NCT05514223

Intervention type: OTHER
Intervention: Biomaterial collection for observational purpose
Description: The semen will be collected to measure the free radical concentration in seminal plasma and sperm together with the diversity of microbiota. Both males with a normal semen analysis (SA) and abnormal SA according to the WHO guidelines (2010) will be included. Blood plasma will be collected to measure systemic radical concentration and all outcomes will be related to lifestyle factors and food intake acquired through hospital charts and routinely conducted questionnaires together with a food frequency Questionnaire (FFQ).
Study: NCT05206201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZY19489 Capsule
Description: Two part study with single and multiple dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Two part study with single and multiple dose
Study: NCT06623032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium-Chain Fatty Acid (MCFA)
Description: The participants will consume Medium-Chain Fatty Acid (MCFA) followed by Long-Chain Fatty Acid (LCFA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium-Chain Fatty Acid (MCFA)
Description: The participants will consume Medium-Chain Fatty Acid (MCFA) followed by Long-Chain Fatty Acid (LCFA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-Chain Fatty Acid (LCFA)
Description: The participants will consume Long-Chain Fatty Acid (LCFA) followed by Medium-Chain Fatty Acid (MCFA).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-Chain Fatty Acid (LCFA)
Description: The participants will consume Long-Chain Fatty Acid (LCFA) followed by Medium-Chain Fatty Acid (MCFA).
Study: NCT05962463

Intervention type: PROCEDURE
Intervention: Canal adductor blockade
Description: The same experienced anesthesiologist has performed all blocks. Always after surgical cleaning of the anteromedial thigh, all participants in this group received single shot ultrasound guided canal adductor blockade. After the blockade, all participants were monitored in our ambulance for the next hour.

Intervention type: PROCEDURE
Intervention: Canal adductor pulsed radio-frequency therapy
Description: The same experienced anesthesiologist has performed all PRF therapy After surgical cleaning of the anteromedial thigh, all participants in this group received ultrasound-guided pulsed radiofrequency therapy. We've previously scanned the adductor canal and chose the middle of the canal as the entry point of the RF 10 cm needle with a 1 cm free tip. After sensory and motor checking all patients have gotten 6 minutes of therapy divided into 3 sequences of 2 minutes of 50 V current and 42ºC. After the treatment, all participants were monitored in our ambulance for the next hour.
Study: NCT05282901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/1 ML Intravenous Solution
Description: Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor vascularization, thus allowing an increased infiltration of the tumor by immune cells and an improved immune response.